Hypoandrogenism in association with diminished functional ovarian reserve

Abstract

This research was supported by the Foundation for Reproductive Medicine, a not-for-profit medical research foundation and intramural funds from the Center for Human Reproduction. N.G. and D.H.B are members of the Board of the Foundation for Reproductive Medicine. N.G., A.W. and D.H.B. received research support, lecture fees and travel support from a variety of pharmaceutical and medical device companies, none in any way related to the issues discussed in this manuscript. N.G. and D.H.B. are listed as co-inventors on two, already granted US user patents, which claim therapeutic benefits from DHEA supplementation in women with DFOR and DOR: both authors are also listed on additional pending patents in regard to DHEA supplementation and on pending patents, claiming diagnostic and therapeutic benefits from the determination of CGG repeats on the FMR1 gene. N.G. is the owner of the Center for Human Reproduction, where this research was performed.

Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarian reserve and is a potential regulator of the immune response in the ovaries

“…Although total androgen concentrations were not associated with pregnancy during DHEA supplementation in women with POI, interaction between DHEA and total and free testosterone also significantly affected pregnancy rates at the start of an IVF cycle (67). Total testosterone is significantly lower in women with POI or abnormal FMR1 genotypes (68). The efficiency of androgen conversion from DHEA to testosterone and the amplitude of testosterone gain are related to pregnancy rates.…”

Improvements in IVF in women of advanced age

“…Since then, low FOR has been defined as a relatively hypoandrogenic condition in need of androgen supplementation (Gleicher et al 2013), and various animal models established the importance of appropriate testosterone levels for normal growth and maturation of small growing follicles (recently reviewed in this journal by Prizant et al 2014). DHEA effects have been attributed to its conversion to testosterone, which synergistically enhances FSH effects on GCs through the androgen receptor (reviewed in Prizant et al 2014, Shohat-Tal et al 2015.…”

The impact of FMR1 gene mutations on human reproduction and development: a systematic review

“…(ii) Heterozygous (het), when only one allele is in the [26][27][28][29][30][31][32][33][34] repeat range. This comprises two sub-genotypes, the hetnorm/high (second allele has >34 repeats) and het-norm/ low (second allele has <26 repeats).…”

“…A deficit of DHEA/T conversion has been identified in a subset of impaired ovarian reserve patients [34,35].…”